Glaukos (FRA:6GJ) Institutional Ownership : 88.10% (As of May. 03, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Glaukos Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Glaukos's institutional ownership is 88.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Glaukos's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Glaukos's Float Percentage Of Total Shares Outstanding is 58.66%.

Glaukos Institutional Ownership Historical Data

The historical data trend for Glaukos's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Institutional Ownership Chart

Glaukos Historical Data

The historical data trend for Glaukos can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	80.16	83.41	84.47	84.02	82.91	82.44	84.48	87.51	87.90	88.10

Glaukos Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Glaukos (FRA:6GJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

GKOS:USA

Address

One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website

https://www.glaukos.com

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos (FRA:6GJ) Headlines

No Headlines